News & Trends - Pharmaceuticals

Australian triple therapy for COVID-19 cure and prevention

Health Industry Hub | August 5, 2020 |
[Total: 1    Average: 5/5]

Pharma News: The Centre for Digestive Disease (CDD) Medical Director Professor Thomas Borody says TGA and FDA approved Ivermectin, which he uses regularly in his hospital, has shown positive results for COVID-19 and should considered immediately to fight the pandemic.

MSD’s Ivermectin was discovered in the 1970s and is on the World Health Organisation (WHO) list of essential medicines.

Professor Borody has used the same methodology with the COVID-19 Ivermectin Triple Therapy as he used when he developed the world’s first cure for peptic ulcers saving millions of lives around the globe.

He says this combination of 3 approved “off the shelf” drugs could be the answer to Australia’s COVID-19 crisis.

Professor Borody said “If nothing else, make it available in aged care homes immediately. Our elderly are at the highest risk and this is a very safe option especially when we have nothing else except ventilators.”

“Also, our frontline workers deserve more protection with a preventative medication like this, and as emergency treatment if they test positive.”

“An Ivermectin tablet can cost as little as $2 – which could make it by far the cheapest, safest, and fastest cure for Australians and the Australian economy.”

Professor Borody is an internationally regarded physician with 4 FDA approved drugs on the US and Australian markets, who is famous for developing the triple therapy that cured peptic ulcerssaving more than 18,000 lives just in Australia and millions internationally.

He said Ivermectin has a good safety profile and in fact the WHO says in a report ‘Mass treatment with ivermectin: an underutilised public health strategy’… “It is time to capitalise on the full public health potential of ivermectin” as an anti-parasitic.

The Journal of Antibiotics a 12 June 2020 report on Ivermectin says “Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2.”

Professor Borody says his research has led him to a triple therapy of Ivermectin, zinc and an antibiotic – which are all TGA and FDA approved – which could be the fastest and safest way to stop the Victorian outbreak within 6-8 weeks.

He said he knows of medical professionals already using it as a preventative therapy themselves.

Professor Borody said “When State and Federal governments are saying they will do whatever it takes then I believe this is a potential life-saver right now.”

“These 3 medications are already approved. They do not need pre-clinical or clinical trials nor additional TGA approvals unless the aim is to combine in a single capsule, for example. Patient treatment programs have been done in the US and elsewhere which indicate it can work within 4-6 days.”

Professor Borody has reviewed the key antiviral scientific research literature and identified the combination of 3 drugs that are in chemists right now and can be prescribed by doctors immediately. The tablets can be taken at home as a preventive treatment by high risk individuals, or by those who test positive to minimise need for hospitalisation at the higher curative dose.

The therapy comprises:

  1. Ivermectin – TGA and FDA approved as an anti-parasitic therapy with an established safety profile since the 1970s. Known as the “Wonder Drug” from Japan.
  2. Zinc
  3. Doxycycline – TGA and FDA approved tetracycline antibiotic that fights infections, such as acne, urinary tract infections, intestinal infections, respiratory infections, eye infections,  gonorrhea,  chlamydia, syphilis, periodontitis (gum disease), and others.

Professor Borody says distribution teams could be deployed in Victoria’s hotspots to treat proven infected patients immediately, and people exposed or at risk could be taking the preventative dose.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Marketing & Strategy

PRIME Award 2020 winners announced

Health Industry Hub | September 24, 2020 |

The first ever virtual PRIME Awards saw the best and brightest healthcare communications work recognised in the pharmaceutical and life […]

More


News & Trends - Pharmaceuticals

Pharma News - Australia’s first Antimicrobial Resistance Network to combat global health threat

Australia’s first Antimicrobial Resistance Network to combat global health threat

Health Industry Hub | September 24, 2020 |

Please log in to Health Industry Hub to view this content in the News menu → Pharmaceuticals sub-menu.

More


News & Trends - Medical Technology

MedTech News - Companies playing an important role in the robot-assisted surgery market

Companies playing an important role in the robot-assisted surgery market

Health Industry Hub | September 23, 2020 |

MedTech News: The market for surgical robots is expected to grow from USD 6.7 billion in 2020 to USD 11.8 […]

More


News & Trends - Pharmaceuticals

Pharma News - Roche acquires Inflazome co-founded by local researcher

Roche acquires Inflazome co-founded by local researcher

Health Industry Hub | September 23, 2020 |

Please log in to Health Industry Hub to view this content in the News menu → Pharmaceuticals sub-menu.

More